VEGFA and non-small cell lung carcinoma: For patients with advanced nonsquamous NSCLC, a combination of platinum-based chemotherapy with bevacizumab, a monoclonal antibody against vascular endothelial growth factor (VEGF), resulted in modest improvements in survival [28].